Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 1,431	$ 1,012
General and administrative	1,234	1,212
Total operating expenses	2,665	2,224
Operating loss	(2,665)	(2,224)
Other income:
Interest income	1	1
Other income	9
Other income	10	1
Net loss	$ (2,655)	$ (2,223)
Net loss per share, basic	$ (1.94)	$ (1.89)
Net loss per share, diluted	$ (1.94)	$ (1.89)
Weighted average number of common shares outstanding, basic (In Shares)	1,370,347	1,178,946
Weighted average number of common shares outstanding, diluted (In Shares)	1,370,347	1,178,946